COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00374296
Recruitment Status : Terminated (The Clinical Development Program for MGCD0103 is being re-evaluated)
First Posted : September 11, 2006
Last Update Posted : July 1, 2015
Information provided by (Responsible Party):
Mirati Therapeutics Inc.

Brief Summary:
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.

Condition or disease Intervention/treatment Phase
Myelogenous Leukemia, Acute Myelodysplastic Syndromes Drug: MGCD0103 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease
Study Start Date : September 2006
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Arm Intervention/treatment
No Intervention: 1
Elderly (≥65 years) untreated arm
Experimental: 2
Relapsed/Refractory Arm
Drug: MGCD0103
MGCD0103 administered orally three-times per week

Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: 1 year (anticipated ]
  2. Response rate [ Time Frame: 1 year (anticipated) ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: 1 year (anticipated) ]
  2. Duration of objective response [ Time Frame: 1 year (anticipated) ]
  3. Pharmacokinetics [ Time Frame: 1 year (anticipated) ]
  4. Pharmacodynamics [ Time Frame: 1 year (anticipated) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologic confirmation of AML or high risk MDS.
  • Elderly cohort (70 years of age or more): no prior chemotherapy treatment for AML/high risk MDS and not currently candidates for intensive chemotherapy.
  • Relapsed/refractory cohort (18 years of age or more): relapsed or refractory to prior treatment.
  • ECOG performance status of 0 or 1.
  • Total bilirubin < 1.5 x upper limit of normal (ULN).
  • AST/SGOT and ALT/SGPT < 2.5 x ULN.
  • Serum creatinine < 1.5 x ULN.
  • Patients must read, understand, and sign a written informed consent form (ICF).
  • Women of childbearing potential and male patients' female partners must use an acceptable method of contraception while on study, and for 3 months after study drug treatment.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Patients with uncontrolled, intercurrent illness, active or uncontrolled infections, or a fever > 38.5C (not due to tumor fever) on the day of scheduled dosing.
  • Patients with serious illnesses or medical conditions, including laboratory results, which, in the investigator's opinion, would interfere with a patient's participation, or with the interpretation of the results.
  • Patients treated with an investigational drug within 30 days prior to study initiation.
  • Known hypersensitivity to HDAC inhibitors or to any of the components of MG-0103.
  • Known HIV or active hepatitis B or C.
  • Any condition that may affect the patient's ability to sign the ICF and undergo study procedures.
  • Any conditions that will put the patient at undue risk or discomfort as a result of adherence to study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00374296

Layout table for location information
United States, Missouri
Veterans Affairs Medical Center
Kansas City, Missouri, United States, 64128
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642-0001
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Ohio State University Medical Center - James Cancer Hospital
Columbus, Ohio, United States, 43210
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Canada, Ontario
Hamilton Health Sciences - McMaster Hospital
Hamilton, Ontario, Canada, L8N 3Z5
UHN - Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M6
Canada, Quebec
Hopital Charles Lemoyne
Greenfield Park, Quebec, Canada, J4V 2H1
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada, H1T 2M4
Hopital Notre-Dame du CHUM
Montreal, Quebec, Canada, H2L 4M1
Sir Mortimer Davis-Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Universite de Sherbrooke, Service d'hematologie
Sherbrooke, Quebec, Canada, J1H 5N4
Sponsors and Collaborators
Mirati Therapeutics Inc.
Layout table for investigator information
Study Director: Gregory Reid, MSc, MBA MethylGene Inc.
Layout table for additonal information
Responsible Party: Mirati Therapeutics Inc. Identifier: NCT00374296    
Other Study ID Numbers: 0103-007
First Posted: September 11, 2006    Key Record Dates
Last Update Posted: July 1, 2015
Last Verified: June 2015
Keywords provided by Mirati Therapeutics Inc.:
Phase II
Acute Myelogenous Leukemia (AML)
High Risk Myelodysplastic Syndromes (MDS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action